292 |
Challenges With Valve-in-Valve TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification |
David Joel Cohen |
Apr. 19. 24 |
291 |
Valve Thrombosis and Valve Degeneration - How to Detect |
Yohei Ohno |
Apr. 19. 24 |
290 |
The UPSTREAM Management of Aortic Stenosis |
Alan C. Yeung |
Apr. 19. 24 |
289 |
Current Status of Valvular and Structural Heart Disease Intervention in Japan: New Insights from the OCEAN-SHD Family |
Kentaro Hayashida |
Apr. 19. 24 |
288 |
Moderate AS in HFrEF: Time-to-Treat is Now and Future Expectation from RCTs |
Nicolas Van Mieghem |
Apr. 19. 24 |
287 |
TAVR-in-TAVR: Planning and Optimizing the Procedure |
Karl Poon |
Apr. 19. 24 |
286 |
Ultra-Minimalist TAVR: Novel Strategy for a Quick Procedure and Short Hospital Stay |
James Flaherty |
Apr. 19. 24 |
285 |
No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight from the OCEAN-TAVI Registry |
Shinichi Shirai |
Apr. 19. 24 |
284 |
The Next Chapter of Vulnerable Plaque Diagnosis and Treatment |
Gary S. Mintz |
Apr. 19. 24 |
283 |
What to Expect with Evolut FX |
Yohei Ohno |
Apr. 19. 24 |